Discovery of analogues of non-β oxidizable long-chain dicarboxylic fatty acids as dual inhibitors of fatty acids and cholesterol synthesis: Efficacy of lead compound in hyperlipidemic hamsters reveals novel mechanism

Nutr Metab Cardiovasc Dis. 2021 Jul 22;31(8):2490-2506. doi: 10.1016/j.numecd.2021.05.024. Epub 2021 Jun 1.

Abstract

Background and aims: Cholesterol and triglycerides are risk factors for developing cardiovascular disease. Therefore, appropriate cells and assays are required to discover and develop dual cholesterol and fatty acid inhibitors. A predictive hyperlipidemic animal model is needed to evaluate mechanism of action of lead molecule for therapeutic indications.

Methods and results: Primary hepatocytes from rat, hamster, rabbit, and humans were compared for suitability to screen compounds by de novo lipogenesis (DNL) using14C-acetate. Hyperlipidemic hamsters were used to evaluate efficacy and mode of action. In rat hepatocytes DNL assay, both the central moiety and carbon chain length influenced the potency of lipogenesis inhibition. In hyperlipidemic hamsters, ETC-1002 decreased plasma cholesterol and triglycerides by 41% and 49% at the 30 mg/kg dose. Concomitant decreases in non-esterified fatty acids (-34%) and increases in ketone bodies (20%) were associated with induction of hepatic CPT1-α. Reductions in proatherogenic VLDL-C and LDL-C (-71% and -64%) occurred partly through down-regulation of DGAT2 and up-regulation of LPL and PDK4. Activation of PLIN1 and PDK4 dampened adipogenesis and showed inverse correlation with adipose mass. Hepatic concentrations of cholesteryl ester and TG decreased by 67% and 64%, respectively. Body weight decreased with concomitant decreases in epididymal fat. Plasma and liver concentrations of ETC-1002 agreed with the observed dose-response efficacy.

Conclusions: Taken together, ETC-1002 reduced proatherogenic lipoproteins, hepatic lipids and adipose tissues in hyperlipidemic hamsters via induction of LPL, CPT1-α, PDK4, and PLIN1, and downregulation of DGAT2. These characteristics may be useful in the treatment of fatty livers that causes non-alcoholic steatohepatitis.

Keywords: ATP citrate Lyase; Adipogenesis; Diacyl glycerol acyl transferase; Fatty acid oxidation; Hamster; Lipogenesis; Perilipin1; Pyruvate dehydrogenase kinase 4.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carnitine O-Palmitoyltransferase / metabolism
  • Cells, Cultured
  • Cholesterol / biosynthesis*
  • Cholesterol / blood
  • Dicarboxylic Acids / pharmacology*
  • Diet, High-Fat
  • Disease Models, Animal
  • Fatty Acids / biosynthesis*
  • Fatty Acids / blood
  • Fatty Acids / pharmacology
  • Hepatocytes / drug effects*
  • Hepatocytes / enzymology
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy*
  • Hyperlipidemias / enzymology
  • Hypolipidemic Agents / pharmacology*
  • Lipogenesis / drug effects*
  • Lipoprotein Lipase / metabolism
  • Male
  • Mesocricetus
  • Perilipin-1 / metabolism
  • Protein Kinases / metabolism
  • Rabbits
  • Rats
  • Rats, Wistar

Substances

  • Dicarboxylic Acids
  • Fatty Acids
  • Hypolipidemic Agents
  • Perilipin-1
  • 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
  • Cholesterol
  • Carnitine O-Palmitoyltransferase
  • Protein Kinases
  • pyruvate dehydrogenase kinase 4
  • Lipoprotein Lipase